CG
PDLI

Caprock Group’s PDL BioPharma, Inc. PDLI Stock Holding History

Caprock Group’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-15,900
Closed -$52K – 432
2019
Q4 		$52K Hold
15,900
– – 0.01% 359
2019
Q3 		$34K Hold
15,900
– – 0.01% 353
2019
Q2 		$50K Sell
15,900
-16,700
-51% -$54.2K 0.01% 346
2019
Q1 		$121K Hold
32,600
– – 0.02% 360
2018
Q4 		$95K Buy
+32,600
New +$89.6K 0.02% 339

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
ECM
Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Caprock Group's PDLI Position: Q1 2020 in Review

Caprock Group sold out of PDL BioPharma, Inc. (PDLI) in Q1 2020, closing a stake of 15,900 shares — an estimated $52K sold.

Caprock Group first reported a position in PDLI in Q4 2018 and held it in 5 quarters. The position peaked at $121K in Q1 2019. 132 funds tracked by Wall St. Rank hold PDLI as of Q1 2020.

  • Caprock Group reported no remaining PDL BioPharma, Inc. position as of Q1 2020 after selling out during the quarter.
  • Caprock Group sold 15,900 PDL BioPharma, Inc. shares in Q1 2020, an estimated $52K.
  • Caprock Group first reported a position in PDL BioPharma, Inc. in Q4 2018 and held it in 5 quarters.
  • Caprock Group's PDL BioPharma, Inc. position peaked at $121K in Q1 2019.
  • 132 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2020.

Based on Caprock Group's 13F filing for Q1 2020, filed 28 Apr 2020.